{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-005046","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.107292+00:00","generated_at":"2026-06-06T08:48:42.675237+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lineage Cell Therapeutics enters $14M registered direct offering at $1.04/share","bullets":["Sale of 13,461,540 common shares at $1.04 each; gross proceeds of $14.0M.","Broadwood Partners (affiliated with director Neal Bradsher) to buy 6,730,770 shares.","Director Don M. Bailey to buy approximately 100,000 shares in the offering.","Closing expected on or about February 8, 2024, subject to customary conditions.","Proceeds to fund clinical trials, R&D, G&A, and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-005046","json":"https://secwatch.observer/filing/0001493152-24-005046.json","markdown":"https://secwatch.observer/filing/0001493152-24-005046.md","text":"https://secwatch.observer/filing/0001493152-24-005046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005046/0001493152-24-005046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005046/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:48:42.675237+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd4c7b085724cf4134372fdcdc1a271f2483e19d","claim":"Lineage Cell Therapeutics, Inc. entered into purchase agreement with certain investors valued at $14.0 million (effective 2024-02-06).","evidence_excerpt":"On February 6, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”) entered into a stock purchase agreement (the “purchase agreement”) with certain investors relating to the purchase and sale in a registered direct offering of an aggregate of 13,461,540 common shares of the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000149315224005046/0001493152-24-005046-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"$14.0 million"},{"label":"Effective","value":"2024-02-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}